Skip to main content
. Author manuscript; available in PMC: 2017 Jul 11.
Published in final edited form as: Adv Pharmacol. 2014 Aug 22;71:203–243. doi: 10.1016/bs.apha.2014.06.002

Figure 4.

Figure 4

Blood–brain barrier disruption (BBBD) increases antibody delivery in the rat model of CNS lymphoma. Rats with intracerebral MC116 xenografts received 90Y-ibritumomab intravenously with or without BBBD. (A) Radiolabel in tumor, brain around tumor (BAT), ipsilateral brain distant to tumor (BDT), and contralateral left hemisphere (LH), was determined at 10 min after antibody administration. There was a significant effect of BBBD in the repeated measures ANOVA model (P=0.0361). (B) Radiolabel localized in BDT is shown at 10 min, 24 h, and 3 days after antibody administration. Reprinted from Muldoon, Lewin, et al. (2011).